Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)

Completed

• Conditions: Diffuse Large B-Cell Lymphoma

• Registration Number: NCT02708732
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

This study is a prospective, cross-sectional survey to be administered to real patients in remission from DLBCL using a 15-minute postal or online survey. The project is designed to describe the impact of DLBCL remission on health utility and quality of life. Data collection will occur over a 4-month period.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-03-10
• Study First Submitted QC: 2016-03-10
• Study First Posted: 2016-03-15
• Study Start: 2016-05-31
• Primary Completion: 2016-10-31
• Study Completion: 2016-10-31
• Status Verified: 2017-04
• Last Update Submitted: 2017-04-19
• Last Update Posted: 2017-04-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 91

Inclusion Criteria

• Adults greater than or equal to (>/=) 18 years of age
• Diagnosis of DLBCL and currently in first remission
• Prior drug treatment for DLBCL

Read More

Exclusion Criteria

• Receiving active treatment for DLBCL
• Relapsed following any treatment for DLBCL

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Health-Related Quality of Life According to European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) Score	Up to 4 months of data collection

Trial Locations

Locations (1)

PH Associates - an OPen Health Company; 🇬🇧 Marlow, United Kingdom